Viking Therapeutics (VKTX)

Executive Summary

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. Its lead asset, VK2735, is a dual GLP-1/GIP receptor agonist in Phase 3 for obesity, addressing a massive market with potential for best-in-class efficacy and tolerability. Positive Phase 2 data showed up to 14.7% mean weight loss at 13 weeks, positioning it competitively against incretin-based therapies. The company also has VK2809, a thyroid hormone receptor beta agonist, in Phase 2b for non-alcoholic steatohepatitis (NASH), and VK0214, a small molecule for X-linked adrenoleukodystrophy (X-ALD) in Phase 1. With a strong balance sheet and no debt, Viking is well-capitalized to advance its pipeline through key value-inflection points. Upcoming catalysts include the initiation of Phase 3 trials for VK2735, top-line data from the ongoing Phase 2b NASH study of VK2809, and potential partnering or licensing deals for VK2735 given the high interest in obesity therapies. The company's focus on proven mechanisms with differentiated profiles, combined with a robust pipeline, supports a favorable risk/reward profile. Success in these programs could position Viking as a major player in the metabolic disease space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 VK2735 Obesity Trial Interim Data80% success
• Q2 2026Phase 2b VK2809 NASH Top-Line Data60% success
• H1 2026Potential VK2735 Partnership or Licensing Deal70% success